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Abstract We have synthesized and characterized peptides de-
rived from complementarity-determining regions (CDRs) of
8D4, a mouse monoclonal antibody against NS3 protease do-
main of hepatitis C virus. 8D4 inhibits enzymatic activity with-
out its cofactor, NS4A peptide. One of the synthetic peptides
derived from CDRs, CDR1 of the heavy-chain (CDR-H1) pep-
tide strongly inhibited NS3 protease activity competitively in the
absence of NS4A and non-competitively in the presence of
NS4A. Moreover, cyclic CDR-H1 peptides bridged by disul¢de
inhibited NS3 protease more potently. The chain length of the
CDR-H1 peptide is critical for strong inhibition, even when the
peptide is circularized. This ¢nding suggests the importance of
peptide conformation. In contrast to a cognate antibody mole-
cule, CDR-derived peptides may provide good ligands for target
molecules by having a tolerance to conformational changes of
the targets caused by cofactor binding or mutation. - 2002
Federation of European Biochemical Societies. Published by
Elsevier Science B.V. All rights reserved.
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1. Introduction
Antibodies use six complementarity-determining regions
(CDRs) in their variable domains to bind with high speci¢city
and a⁄nity to antigens [1^4]. The well-studied antigen-bind-
ing sites of antibodies hold considerable promise as model
systems for the design of peptides with antibody-like recogni-
tion mechanisms [5]. The small repertoire of main-chain con-
formations of CDRs, referred to as ‘canonical structures’ [6^
8], suggests that sequences of CDRs provide structural tem-
plates for designing low-molecular-weight lead compounds.
Several recent reports have shown that synthetic peptides de-
rived from CDR sequences have binding properties similar to
those of the intact antibody [9^14]. This ¢nding indicates that
CDR-derived peptides can overcome several disadvantages of
full antibodies, including time-consuming puri¢cation steps,
instability of antibodies and antibody-producing hybridomas,
and immunoreactivity.
Non-structural protein (NS) 3 of hepatitis C virus (HCV) is
a multifunctional, virus-speci¢c protein that contains serine
protease activity in its N-terminal region and accounts for
processing of the viral polyprotein at four cleavage sites,
NS3/4A, NS4A/4B, NS4B/5A, and NS5A/5B. NS3 also con-
tains helicase and nucleic-acid-stimulated nucleoside triphos-
phatase activities in its C-terminal region (see references [15^
17] for review). NS3 protease requires the NS4A peptide as a
cofactor for e⁄cient cleavage of the viral polyprotein [18^19].
X-ray crystallographic analysis and nuclear magnetic reso-
nance spectroscopic analysis of the NS3 protease domain
with and without the NS4A cofactor have provided a re¢ned
picture of the NS3 structure, demonstrating that the overall
topology is similar and forms N-terminal (approximately res-
idues 1^93) and C-terminal (residues 94^180), six-stranded,
anti-parallel L-barrels that are packed like those of chymo-
trypsin-like serine proteases [20^22]. However, several loops
found in other chymotrypsin family proteases, which play a
critical role in de¢ning the shapes of the non-prime-side sub-
strate-binding pockets, are missing from NS3, rendering the
substrate-binding groove relatively featureless and therefore
making the design of low-molecular-weight inhibitors chal-
lenging [20]. The interaction of NS4A with NS3 was shown
to induce conformational changes in NS3 that involve both a
structural reorganization of the N-terminal domain and a re-
arrangement of the protease catalytic site [20,22].
Recently, we developed the monoclonal antibody 8D4,
which recognizes the active site of HCV NS3 protease [23].
This immunoglobulin inhibits NS3 protease activity relatively
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strongly, with an inhibition constant (Ki) of 39 nM. We have
also reported the DNA sequence analysis, bacterial expres-
sion, and functional characterization of the antibody variable
domain fragment (Fv) and single-chain antibody (scFv) of
8D4, demonstrating that the Fv had an inhibition pro¢le al-
most identical to that of the entire IgG [24]. However, an
observed reduction of more than 1000-fold in the inhibitory
activity of the antibody against NS3^4A complex is due to
conformational changes to the NS3 caused by binding to
NS4A [23]. To date, no antibody molecule except for 8D4
has been prepared against NS3^4A protease, perhaps because
of its featureless antigenic structure. Thus, engineering of 8D4
or CDR peptides would be promising for construction of in-
hibitors.
We report the inhibitory activities of synthetic peptides de-
rived from six CDRs of the antibody 8D4. One of the pep-
tides, CDR-H1 peptide shows inhibitory activity toward NS3
and NS3^4A complex, with Ki values of 3.5 and 6.5 WM,
respectively. Circularization of the CDR-H1 peptides by in-
troducing Cys residues into their N- and C-terminus increased
the inhibitory activity by more than four times. The peptides
could provide structural templates for designing low-molecu-
lar-weight lead compounds of NS3^4A-speci¢c inhibitors as
anti-HCV agents.
2. Materials and methods
2.1. Peptides
All CDR peptides, listed in Tables 1 and 2, were provided by
Sawady Technology (Tokyo, Japan), in which these peptides have
been synthesized with an automated multiple peptide synthesizer
(SYRO II), circularized with 5,5P-dithiobis-2-nitrobenzoic acid
(DTNB) and puri¢ed by high-performance liquid chromatography
(HPLC). Design of the peptide sequence is based on a previous report
of antibody sequences [24]. Substrate peptide of NS3 protease and
NS4A peptide, used for enzymatic assays were synthesized and puri-
¢ed by HPLC using the Peptide Institute Inc. (Osaka, Japan).
2.2. Production and puri¢cation of active NS3 protease
DNA fragments encoding the N-terminal protease domain (1^190
residues) of NS3 of HCV IIJ [25] were cloned into the expression
vector pMT1. The vector had been constructed by replacing the tac
promoter of pMK2 with a tryptophan promoter to overproduce an
N-terminal domain with a hexahistidine tag (His6-NS31190) [23]. Es-
cherichia coli (strain JM109) cells transformed with the resulting plas-
mid were cultured overnight at 25‡C in M9 medium (60 g Na2HPO4,
30 g KH2PO4, 10 g NH4Cl, and 5 g NaCl per liter of distilled water,
pH 7.4) containing ampicillin (100 Wg/ml) and supplemented with
0.2% casamino acids, 0.2% glucose, 1 mM MgSO4, 0.1 mM CaCl2,
and 1 mM thiamine. The cells were further propagated in 3.6 l of the
same medium for 15 h at 25‡C. They were then exposed to 25 Wg/ml
3-indoleacrylic acid and cultured for an additional 8 h at 20‡C. Cells
were then harvested, suspended in bu¡er [50 mM TrisWHCl (pH 7.5),
0.3 M NaCl, 20 mM imidazole, 10% glycerol], and disrupted by son-
ication on ice. His6-NS31190 was then puri¢ed by metal chelate af-
¢nity (Ni^NTA Super£ow, Qiagen) and ion exchange chromatogra-
phy (S-Sepharose Fast£ow, Pharmacia). Eluted fractions were
collected in CHAPS bu¡er [50 mM TrisWHCl (pH 7.5), 10% glycerol,
0.5% 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate]
and pooled. NS3 protease thus prepared showed s 90% purity as
assessed by sodium dodecyl sulfate^polyacrylamide gel electrophoresis
(SDS^PAGE; data not shown), and was stored at 370‡C after the
addition of an equal volume of glycerol.
2.3. Inhibition assay of NS3-dependent cleavage of a peptide substrate
by CDR-derived peptides
A synthetic peptide carrying the NS5A/5B cleavage site and having
a £uorescent moiety at its N-terminus (£uorophore 2-aminobenzoy-
l[Abz]-EDVVECSMSY-NH2) was used as substrate. The reaction
mixture contained 50 mM TrisWHCl (pH 8.5), 30 mM NaCl, 2%
CHAPS, and 5% Glycerol. The NS3 protease (38 nM) was preincu-
bated in the presence or absence of 100 WM of CDR-derived peptides
and the 5 WM of NS4A peptide (H-LTTGSVVIVGRIILSGR-
PAVVPD-OH; Pep4A1840, designated as NS4A) [26] for 10 min at
room temperature in a total volume of 80 Wl. The reaction was ini-
tiated by the addition of 20 Wl of the substrate peptide dissolved in 50
mM TrisWHCl (pH 8.5), 30 mM NaCl, 5 mM CaCl2, and 25 mM
dithiothreitol (DTT). The ¢nal concentration of the peptide substrate
in the reaction mixture was 0.025 mM in the presence of NS4A or 0.2
mM in its absence, unless otherwise indicated. The reaction was con-
tinued at 37‡C for 15 min with NS4A or 60 min without, and
quenched by the addition of 100 Wl of 0.5% tri£uoroacetic acid
(TFA). The £uorescent reaction product (Abz-EDVVEC-OH) was
then separated on a reverse-phase HPLC apparatus equipped with a
C4 column (4.6U50 mm, Vydac) by elution at a £ow rate of 2 ml/min
with an aqueous solution containing 14% acetonitrile and 0.1% TFA.
The £uorescence signal was detected by a spectro£uorometric detector
(Shimadzu, Kyoto, Japan) with excitation and emission wavelengths
at 320 and 425 nm, respectively. The amount of the product was
quanti¢ed by integration of the chromatogram in relation to a chemi-
cally synthesized peptide standard with a structure identical to that of
the cleavage product. Precise analyses of the inhibitory activity of
CDR peptides were performed under the same conditions described
above, with varying concentrations of CDR peptides before addition
of the synthetic substrate peptide. Steady-state kinetic parameters and
the Ki value were determined by Lineweaver^Burk plot and Dixon
plot analyses, respectively [23].
2.4. Inhibition assay of NS3-dependent cleavage of a peptide substrate
by circularized CDR peptides
The experimental procedures of the inhibition assay using circular-
ized CDR peptides were in principle followed by the same conditions
described above. To determine the e¡ect of circularization of the pep-
tides on the inhibitory activity, we reduced the circularized CDR pep-
tides with 40 mM DTT for 30 min, then assayed the inhibitory activ-
ity as described above.
Table 1
Amino acid sequences of linear peptides derived from CDRs of
antibody 8D4
Peptidea Sequenceb
CDR-H1 (15) H-GYSFTDYVLIWVKQS-OH
CDR-H2 (17) H-NSNPYYGRTSYNLKFKG-OH
CDR-H3 (15) H-CARGGFYAMDYWQGQG-OH
CDR-L1 (16) H-GSSKSLLHSDGNTYLY-OH
CDR-L2 (15) H-LLIYRMSNLASGVPD-OH
CDR-L3 (14) H-YYCMQHLEYPYTFG-OH
CDR-H1-7 (7) H-TDYVLIW-OH
CDR-H1-5 (5) H-DYVLI-OH
aValues in parentheses are the numbers of residues in each peptide.
bCDR sequences are underlined, and other sequences are derived
from the sequence of parental antibody 8D4.
Table 2
Amino acid sequences of circularized peptides derived from CDR-
H1 of antibody 8D4
aValues in parentheses are the number of residues in each peptide.
bCDR sequences are underlined, and other sequences are derived
from the sequence of parental antibody 8D4. Two cysteines for cir-
cularization by disul¢de bond formation are combined with a line.
cFrom Table 1.
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3. Results
3.1. E¡ect of CDR-derived peptides on NS3-dependent
cleavage of a peptide substrate
We assessed the abilities of the CDR-derived peptides listed
in Table 1 to inhibit the NS3 protease activity toward a syn-
thetic peptide (Abz-EDVVECSMSY-NH2) containing the
NS5A/5B cleavage site as a substrate in the absence or pres-
ence of 5 WM NS4A. As a result, CDR-H1 peptide inhibited
the enzymatic activity of NS3 protease in both the absence
and presence of NS4A. We further examined the extent of
inhibition by CDR-derived peptides in the absence and pres-
ence of 5 WM NS4A (Fig. 1B). CDR-H1 peptide had inhibi-
tory activity toward NS3 protease in a dose-dependent man-
Fig. 1. A: Pro¢le of inhibition by linear CDR peptides of hexahistidine-tagged NS31190 protease with (solid bar) or without NS4A (open bar).
A 38 nM solution of NS3 protease in 50 mM TrisWHCl (pH 8.5) containing 30 mM NaCl and 2% CHAPS was preincubated for 10 min with
100 WM of each CDR peptide. The reactions were started by addition of 0.2 mM oligopeptide substrate S3 (Abz-EDVVECSMSY-NH2, where
Abz is £uorophore 2-aminobenzoyl). The mixture was incubated for 1 h, and the enzymatic reaction was terminated by addition of an equal
volume of 0.1% TFA. The N-terminal cleavage product of S3 was detected by the £uorescence of Abz (Vex = 320 nm, Vem = 425 nm) in HPLC
analysis and quanti¢ed as the ratio of the integrated area denoting the cleavage product to that of a known quantity of standard. B: Dose de-
pendency of the inhibitory activity of CDR-H1 and CDR-L1 peptides with NS4A. Assays were performed under the same conditions as de-
scribed above, with varying concentrations of CDR peptides before addition of the enzyme. C: Dose dependency of the inhibitory activity of
CDR-H1, -H1-5, and -H1-7 peptides with NS4A. Assays were performed under the same conditions described above, with varying concentra-
tions of CDR peptides before addition of the enzyme. Symbols used: solid circle, CDR-H1; open circle, CDR-H1-5; solid square, CDR-H1-7.
Fig. 2. Lineweaver^Burk plot analyses of the inhibition of linear CDR-H1 peptides for NS3 protease without (A) or with NS4A (B). [S] is con-
centration of oligopeptide substrate (Abz-EDVVECSMSY-NH2, where Abz is £uorophore 2-aminobenzoyl). See reference [23] for details.
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ner in both the absence and presence of the NS4A peptide
(Fig. 1B). This result suggests that CDR-H1 is tolerant to
structural changes. CDR-H1-derived peptides with 5 and 7
residues showed reduced inhibition (Fig. 1C), suggesting the
importance of the remaining residues within CDR-H1 for
strong inhibition.
We then conducted steady-state kinetic experiments to ana-
lyze the mechanism of inhibition by CDR-H1 in the absence
and presence of NS4A. As shown in Fig. 2A, CDR-H1
showed linear competitive inhibition of the proteolytic cleav-
age of the peptide substrate by the protease without NS4A
cofactor, indicating that CDR-H1 directly blocked the bind-
ing of the substrate peptide in the absence of NS4A, in a
competitive inhibitory manner. On the other hand, as shown
in Fig. 2B, CDR-H1 inhibited the NS3 protease activity in the
presence of NS4A non-competitively. The Ki values of CDR-
H1 inhibition of the protease, as determined by Dixon plot
analysis, were 3.5 WM in the absence of the cofactor and 6.5
WM in its presence (Fig. 3). These results indicate that CDR-
H1 has relatively strong inhibitory activity toward NS3 pro-
tease in both the absence and the presence of NS4A cofactor,
using di¡erent mechanisms of inhibition.
3.2. E¡ect of circularization of CDR-H1-derived peptides on
the inhibitory activity
We next synthesized 4 CDR-H1-derived peptides circular-
ized with a disul¢de bond by introducing Cys residues into the
N- and C-terminus of the peptides (Table 2). We examined
the inhibitory activity of the circularized peptides toward NS3
protease in the absence or presence of NS4A cofactor. As
shown in Fig. 4, CDR-H1C13, with 13 amino acids, had en-
Fig. 3. Estimation of Ki of linear CDR-H1 peptide without (A) or with NS4A (B). See reference [23] for details.
Fig. 4. Pro¢le of inhibition by cyclic CDR-H1 peptides of NS3 pro-
tease without (A) or with NS4A (B). A 38 nM solution of NS3 pro-
tease in 50 mM TrisWHCl (pH 8.5) containing 30 mM NaCl and 2%
CHAPS was preincubated for 10 min with various concentrations of
cyclic CDR peptides, and the reactions were started by addition of
0.2 mM oligopeptide substrate S3 (Abz-EDVVECSMSY-NH2,
where Abz is £uorophore 2-aminobenzoyl). The mixture was incuba-
ted for 1 h, and the enzymatic reaction was terminated by addition
of an equal volume of 0.1% TFA. The N-terminal cleavage product
of S3 was detected by the £uorescence of Abz (Vex = 320 nm,
Vem = 425 nm) in HPLC analysis and quanti¢ed as the ratio of the
integrated area denoting the cleavage product to that of a known
quantity of standard.
Fig. 5. E¡ect of DTT preincubation on the inhibitory activity of cy-
clic CDR-H1 peptides toward NS3 protease in the presence of
NS4A. Open bar, without DTT incubation; solid bar, with DTT in-
cubation. Each peptide was preincubated with 40 mM DTT for 30
min, and enzymatic activity of NS3 was assayed as described in Sec-
tion 2.
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hanced a⁄nity for NS3 protease in both the absence (Fig. 4A)
and presence (Fig. 4B) of NS4A, with a IC50 value of 1^3 WM.
The other peptides had less inhibitory activity. This result
suggests that CDR-H1C13 has an appropriate conformation
for strong inhibition of the protease activity.
To determine the e¡ect of circularization of the peptides on
the inhibitory activity, we reduced the circularized CDR pep-
tides, and the inhibitory activity has been assayed (Fig. 5).
Reduction of the peptides did not decrease their inhibitory
activity. This result strongly suggests that the conformation
of the CDR peptides created by their amino acid sequences is
critical for binding activity toward the target.
We then conducted kinetic experiments to analyze the
mechanism of inhibition by CDR-H1C13 in the absence and
presence of NS4A. As shown in Fig. 6, CDR-H1C13 inhibited
the enzymatic activity of NS3 non-competitively in both the
absence and presence of NS4A. Dixon plot analysis showed
that CDR-H1C13 has a Ki for NS3 protease of 0.9 WM in the
presence of NS4A peptide and 1.5 WM in its absence (Fig. 7).
4. Discussion
We have shown that a peptide derived from the antibody
CDR, CDR-H1 has strong inhibitory activity toward HCV
NS3 protease. The peptide has fewer than 20 amino acids
(Table 1), which makes it feasible for development of protease
inhibitors. The parental antibody 8D4 has strong inhibitory
activity toward NS3 in the absence of NS4A cofactor. In the
presence of the cofactor, conformational changes to NS3 via
NS4A binding reduce the inhibition [23,24]. However, our
results clearly indicate that CDR-H1 and the circularized
CDR-H1C13 can bind to the antigen in both the absence
and the presence of the cofactor. This ¢nding indicates that
CDR-derived peptides derived from the parental antibody
molecules can recognize cognate binding sites even if confor-
mational changes are induced by cofactor binding.
The candidate recognition site of the parental antibody 8D4
has been proposed as the sequential linear peptide chain
DQDLV (from site 79 to 83 of NS3), which includes one of
the catalytic residues of NS3 protease, Asp81 [23]. 8D4 inhib-
ited NS3 protease competitively. Our results indicate that
CDR-H1 inhibits the protease activity competitively, suggest-
ing that CDR-H1 recognizes the region around Asp81. On the
other hand, restriction of the conformation of CDR-H1 by
circularization enhanced the inhibitory activity, even though
the inhibition was non-competitive, suggesting that cyclic
CDR-H1 recognizes a distinct region on the substrate-binding
site. Recent reports of the solution structures of NS3 and
single-chain NS3^4A proteases have suggested that residues
Val51-Asp81 of the NS3^4A protease are in a slow exchange
with an NS4A-free conformation of NS3, but only a few
structural rearrangements around Asp81 have been observed
[27^30]. Therefore, it might be proper to conclude that the
cyclic CDR-H1 peptide recognizes a certain conformation of
the region around Asp81 in a di¡erent manner from the way
the linear peptide does so.
Fig. 6. Lineweaver^Burk plot analyses of the inhibition by CDR-H1C13 of NS3 protease without (A) or with NS4A (B).
Fig. 7. Estimation of Ki of cyclic CDR-H1C13 peptide without (A) or with NS4A (B).
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The sequence around CDR-H1 is SFTDYVLIWVK (CDR
region is underlined; Table 2). The recent discovery of potent
peptide inhibitors has shown that the inhibitor was derived
from the N-terminal region of the substrate (called the
P region) upon cleavage by NS3^4A, i.e. product inhibitors
[31]. Interestingly, the sequence of substrate NS4A/4B is DE-
MEE (from P6 to P2), and the optimized natural amino acid
sequences are: D(Y/E)(L/I/V)(I/L/E)(L/D/E) [31]. The results
have shown that the optimized sequences shared high homol-
ogy with the sequence of CDR-H1 (DYVLI) of the antibody
8D4. Shortening the length of CDR-H1 (i.e. CDR-H1-7 and
CDR-H1-5, Table 1) dramatically reduced the inhibitory ac-
tivity toward NS3 in the absence and presence of NS4A. This
¢nding indicates the signi¢cant contribution of other amino
acids in CDR-H1 to the inhibition of enzymatic activity, per-
haps through maintaining the loop structure. CDR-H1C17
and CDR-H1C9 had less inhibitory activity than CDR-
H1C13. Thus, the conformation of CDR-H1C13 might be
appropriate for binding to the antigen in a similar manner
to CDR-H1-15 and the cognate antibody. The canonical
structure of CDR-H1 might be critical for strong inhibition
of NS3 and NS3^4A.
Our results highlight the usefulness of CDR-derived pep-
tides for the design of peptides targeted to speci¢c molecules.
Several CDR-derived peptides have been used to inhibit re-
ceptor-ligand interaction or cell adhesion [9^14]. A recent el-
egant peptide design achieved by combining a rational design
approach based on CDR with a combinatorial technology
produced matured peptides with a higher a⁄nity at a smaller
size [32]. Incorporation of non-natural amino acids or other
organic compounds into CDR-derived peptides would be
promising for enhancement of a⁄nity. Crystal structures of
antigen^antibody complexes have shown that only a few res-
idues in CDRs make a critical contribution to the Gibbs en-
ergy of interactions [2,3,33]. Therefore, at a cost of some en-
ergy loss, CDR peptides might be promising for the design of
target-speci¢c peptides.
In conclusion, a CDR peptide, CDR-H1, derived from the
NS3 protease antibody 8D4, strongly inhibits the protease
activity competitively in the absence of the cofactor NS4A
and non-competitively in the presence of NS4A. The results
suggest the signi¢cance of conformation of the peptide. CDR-
derived peptides may provide good ligands for target mole-
cules by having a tolerance to conformational changes of the
targets caused by cofactor binding or mutation.
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